Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CTH | P32929 | 1/20 | 0.42 |
| ▸ | CBS | P35520 | 1/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10555403 | 0.98 | THRB (0.44) | TSHRCTHCBSTHPOTHRB | |
| Oxalic Acid SCHEMBL11350983 | 0.93 | TSHR (0.42) | TSHRCTHCBSTHPOTHRB | |
| SCHEMBL3695618 | 0.82 | TSHR (0.36) | TSHRCTHCBSTHPOTHRB | |
| SCHEMBL10675042 | 0.81 | CYP2D6 (0.33) | DGAT1CYP2D6HDAC3HDAC1HDAC2 | |
| SCHEMBL6688426 | 0.79 | DGAT1 (0.37) | DGAT1CYP2D6HDAC3HDAC1HDAC2 | |
| SCHEMBL22107474 | 0.79 | APLNR (0.31) | APLNR | |
| SCHEMBL20111804 | 0.78 | CYP2D6 (0.31) | DGAT1CYP2D6HDAC3HDAC1HDAC2 | |
| SCHEMBL5547017 | 0.77 | DGAT1 (0.36) | DGAT1CYP2D6HDAC3HDAC1HDAC2 | |
| SCHEMBL494582 | 0.77 | DGAT1 (0.41) | TSHRDGAT1CYP2D6HDAC3HDAC1 | |
| SCHEMBL27639930 | 0.77 | HDAC3 (0.38) | DGAT1CYP2D6HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112225795-A | 6-hydroxy sulfate melatonin derivative and preparation method and application of immunogen and specific antibody thereof | 湖南苏阳医疗科技有限公司 | 2021-01-15 | — | — | CN | claimed |
| US-20250243161-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| US-12269800-B2 | Delivery of therapeutic alkaloid compounds | SENSORIUM THERAPEUTICS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20250051277-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| US-20240246910-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. | 2024-07-25 | — | — | US | disclosed |
| US-20240228785-A1 | Fluorogenic pH-Sensitive Compounds and Their Methods of Use | Life Technologies Corporation | 2024-07-11 | — | — | US | disclosed |
| US-20240228785-A1 | Fluorogenic pH-Sensitive Compounds and Their Methods of Use | Life Technologies Corporation | 2024-07-11 | — | — | US | disclosed |
| US-11999694-B2 | Delivery of therapeutic alkaloid compounds | SENSORIUM THERAPEUTICS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| CN-117916231-A | Compounds for inhibiting or degrading target proteins, compositions comprising the same, methods of making and methods of using the same | 纽力克斯治疗公司 | 2024-04-19 | — | — | CN | disclosed |
| EP-4334302-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | Nurix Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-4316019-A | AMIDATION BY A 2-ALKOXYIMINO-2-THIAZOLYLACETIC ACID | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1982-02-16 | — | — | US | disclosed |
| US-4304770-A | Syn-isomer of 3,7-disubstituted-3-cephem-4-carboxylic acid compounds and processes for the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-12-08 | — | — | US | disclosed |
| US-4294960-A | 7-[2-(2-Aminothiazol-4-yl)-2-cyclopentyloxyiminoacetamido]-3-cephem-4-carboxylic acid (synisomer) | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-10-13 | — | — | US | disclosed |
| US-4279818-A | CEPHALOSPORINS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-07-21 | — | — | US | disclosed |
| EP-0030630-A2 | 7-Acylamino-3-vinylcephalosporanic acid derivatives, processes for their preparation, pharmaceutical compositions containing them; their starting compounds and their preparation | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-06-24 | — | — | EP | disclosed |
| US-4166115-A | BACTERICIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1979-08-28 | — | — | US | disclosed |
| US-4165430-A | HIGH ACTIVITY AGAINST GRAMNEGATIVE BACTERIA | GLAXO LABORATORIES LIMITED (GB) | 1979-08-21 | — | — | US | disclosed |
| US-4144393-A | 3-Acetoxymethyl cephalosporins having at position-7 a carboxy substituted α-etherified hydroxyiminoarylacetamido group | GLAXO LABORATORIES LIMITED (GB) | 1979-03-13 | — | — | US | disclosed |
| US-4144392-A | Cephalosporins having at position-7 a carboxy substituted α-etherified hydroxyimino-arylacetamido group and at position-3 the residue of a sulphur nucleophile | GLAXO LABORATORIES LIMITED (GB) | 1979-03-13 | — | — | US | disclosed |
| US-4103084-A | ANTIBIOTICS | GLAXO LABORATORIES LIMITED (GB) | 1978-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051277-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | PNMT, HNMT, NNMT | TSHR 4599/4885CTH 3519/4885CBS 3150/4885 |
| US-20250243161-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | PNMT, HNMT, NNMT | TSHR 4599/4885CTH 3519/4885CBS 3150/4885 |
| US-20240246910-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | PNMT, HNMT, NNMT | TSHR 4599/4885CTH 3519/4885CBS 3150/4885 |
| US-12269800-B2 | Delivery of therapeutic alkaloid compounds | PNMT, HNMT, NNMT | TSHR 4599/4885CTH 3519/4885CBS 3150/4885 |
| US-11999694-B2 | Delivery of therapeutic alkaloid compounds | PNMT, HNMT, NNMT | TSHR 4599/4885CTH 3519/4885CBS 3150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.